Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) — Stella

Home/Cutaneous Squamous Cell Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Cutaneous Squamous Cell Carcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Key details

Phase

Early testing / Safety & dosing

Sponsor

Falo, Louis, MD

Collaborators

National Cancer Institute (NCI)

Enrollment target

~48 participants

Started

September 2023

Primary completion

March 2027

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.